Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Antigen delivery format variation and formulation stability through use of a hybrid vector.

Beitelshees M, Hill A, Li Y, Chen M, Ahmadi MK, Smith RJ Jr, Andreadis ST, Rostami P, Jones CH, Pfeifer BA.

Vaccine X. 2019 Jan 30;1:100012. doi: 10.1016/j.jvacx.2019.100012. eCollection 2019 Apr 11.

2.

Loading and Releasing Ciprofloxacin in Photoactivatable Liposomes.

Ghosh S, Qi R, Carter KA, Zhang G, Pfeifer BA, Lovell JF.

Biochem Eng J. 2019 Jan 15;141:43-48. doi: 10.1016/j.bej.2018.10.008. Epub 2018 Oct 11.

PMID:
31105464
3.

Engineering Heterologous Production of Salicylate Glucoside and Glycosylated Variants.

Qi R, Pfeifer BA, Zhang G.

Front Microbiol. 2018 Sep 20;9:2241. doi: 10.3389/fmicb.2018.02241. eCollection 2018.

4.

Engineering a Next-Generation Glycoconjugate-Like Streptococcus pneumoniae Vaccine.

Hill AB, Beitelshees M, Nayerhoda R, Pfeifer BA, Jones CH.

ACS Infect Dis. 2018 Nov 9;4(11):1553-1563. doi: 10.1021/acsinfecdis.8b00100. Epub 2018 Sep 14.

PMID:
30180541
5.

Standardization of Pneumococcal Biofilm Release to PncO Expression, a Predictive Measurement of Virulence.

Hill A, Beitelshees M, Pfeifer BA, Jones CH.

Infect Immun. 2018 Aug 22;86(9). pii: e00494-18. doi: 10.1128/IAI.00494-18. Print 2018 Sep.

6.

Phenotypic Variation during Biofilm Formation: Implications for Anti-Biofilm Therapeutic Design.

Beitelshees M, Hill A, Jones CH, Pfeifer BA.

Materials (Basel). 2018 Jun 26;11(7). pii: E1086. doi: 10.3390/ma11071086. Review.

7.

Broadened glycosylation patterning of heterologously produced erythromycin.

Fang L, Zhang G, El-Halfawy O, Simon M, Brown ED, Pfeifer BA.

Biotechnol Bioeng. 2018 Nov;115(11):2771-2777. doi: 10.1002/bit.26735. Epub 2018 Sep 15.

8.

Time-series lipidomic analysis of the oleaginous green microalga species Ettlia oleoabundans under nutrient stress.

Matich EK, Ghafari M, Camgoz E, Caliskan E, Pfeifer BA, Haznedaroglu BZ, Atilla-Gokcumen GE.

Biotechnol Biofuels. 2018 Feb 6;11:29. doi: 10.1186/s13068-018-1026-y. eCollection 2018.

9.

Pressing diseases that represent promising targets for gene therapy.

Beitelshees M, Hill A, Rostami P, Jones CH, Pfeifer BA.

Discov Med. 2017 Dec;24(134):313-322. Review.

10.

Reconstitution of Kinamycin Biosynthesis within the Heterologous Host Streptomyces albus J1074.

Liu X, Liu D, Xu M, Tao M, Bai L, Deng Z, Pfeifer BA, Jiang M.

J Nat Prod. 2018 Jan 26;81(1):72-77. doi: 10.1021/acs.jnatprod.7b00652. Epub 2018 Jan 17.

PMID:
29338229
11.

Comprehensive vaccine design for commensal disease progression.

Jones CH, Zhang G, Nayerhoda R, Beitelshees M, Hill A, Rostami P, Li Y, Davidson BA, Knight P 3rd, Pfeifer BA.

Sci Adv. 2017 Oct 18;3(10):e1701797. doi: 10.1126/sciadv.1701797. eCollection 2017 Oct.

12.

Heterologous erythromycin production across strain and plasmid construction.

Fang L, Guell M, Church GM, Pfeifer BA.

Biotechnol Prog. 2018 Jan;34(1):271-276. doi: 10.1002/btpr.2567. Epub 2017 Oct 13.

13.

Yersiniabactin metal binding characterization and removal of nickel from industrial wastewater.

Moscatello NJ, Pfeifer BA.

Biotechnol Prog. 2017 Nov;33(6):1548-1554. doi: 10.1002/btpr.2542. Epub 2017 Sep 4.

PMID:
28840649
14.

Increased production of yersiniabactin and an anthranilate analog through media optimization.

Moscatello N, Qi R, Ahmadi MK, Pfeifer BA.

Biotechnol Prog. 2017 Sep;33(5):1193-1200. doi: 10.1002/btpr.2496. Epub 2017 Jun 12.

PMID:
28547883
15.

Bimodal Targeting Using Sulfonated, Mannosylated PEI for Combined Gene Delivery and Photodynamic Therapy.

Chitgupi U, Li Y, Chen M, Shao S, Beitelshees M, Tan MJ, Neelamegham S, Pfeifer BA, Jones C, Lovell JF.

Photochem Photobiol. 2017 Mar;93(2):600-608. doi: 10.1111/php.12688. Epub 2017 Feb 7.

16.

Editorial overview: Pharmaceutical biotechnology: New approaches for dynamic disease targets.

Pfeifer BA, Tang Y.

Curr Opin Biotechnol. 2016 Dec;42:vi-vii. doi: 10.1016/j.copbio.2016.11.002. Epub 2016 Nov 14. No abstract available.

PMID:
27856096
17.

Improved heterologous production of the nonribosomal peptide-polyketide siderophore yersiniabactin through metabolic engineering and induction optimization.

Ahmadi MK, Pfeifer BA.

Biotechnol Prog. 2016 Nov;32(6):1412-1417. doi: 10.1002/btpr.2369. Epub 2016 Oct 28.

PMID:
27681485
18.

E. coli metabolic engineering for gram scale production of a plant-based anti-inflammatory agent.

Ahmadi MK, Fang L, Moscatello N, Pfeifer BA.

Metab Eng. 2016 Nov;38:382-388. doi: 10.1016/j.ymben.2016.10.001. Epub 2016 Oct 5.

PMID:
27718358
19.

In situ pneumococcal vaccine production and delivery through a hybrid biological-biomaterial vector.

Li Y, Beitelshees M, Fang L, Hill A, Ahmadi MK, Chen M, Davidson BA, Knight P 3rd, Smith RJ Jr, Andreadis ST, Hakansson AP, Jones CH, Pfeifer BA.

Sci Adv. 2016 Jul 1;2(7):e1600264. doi: 10.1126/sciadv.1600264. eCollection 2016 Jul.

20.

Directed vaccination against pneumococcal disease.

Li Y, Hill A, Beitelshees M, Shao S, Lovell JF, Davidson BA, Knight PR 3rd, Hakansson AP, Pfeifer BA, Jones CH.

Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):6898-903. doi: 10.1073/pnas.1603007113. Epub 2016 Jun 6.

21.

Enhancing vaccine effectiveness with delivery technology.

Beitelshees M, Li Y, Pfeifer BA.

Curr Opin Biotechnol. 2016 Dec;42:24-29. doi: 10.1016/j.copbio.2016.02.022. Epub 2016 Mar 6. Review.

22.

Recent progress in therapeutic natural product biosynthesis using Escherichia coli.

Ahmadi MK, Pfeifer BA.

Curr Opin Biotechnol. 2016 Dec;42:7-12. doi: 10.1016/j.copbio.2016.02.010. Epub 2016 Mar 1. Review.

PMID:
26942861
23.

The Continuing Development of E. coli as a Heterologous Host for Complex Natural Product Biosynthesis.

Zhang H, Fang L, Osburne MS, Pfeifer BA.

Methods Mol Biol. 2016;1401:121-34. doi: 10.1007/978-1-4939-3375-4_8.

PMID:
26831705
24.

Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors.

Hill AB, Chen M, Chen CK, Pfeifer BA, Jones CH.

Trends Biotechnol. 2016 Feb;34(2):91-105. doi: 10.1016/j.tibtech.2015.11.004. Epub 2015 Dec 23. Review.

25.

Tailoring pathway modularity in the biosynthesis of erythromycin analogs heterologously engineered in E. coli.

Zhang G, Li Y, Fang L, Pfeifer BA.

Sci Adv. 2015 May 29;1(4):e1500077. doi: 10.1126/sciadv.1500077. eCollection 2015 May.

26.

Molecular variation of the nonribosomal peptide-polyketide siderophore yersiniabactin through biosynthetic and metabolic engineering.

Ahmadi MK, Fawaz S, Fang L, Yu Z, Pfeifer BA.

Biotechnol Bioeng. 2016 May;113(5):1067-74. doi: 10.1002/bit.25872. Epub 2015 Nov 20.

PMID:
26524346
27.

Production of the polyketide 6-deoxyerythronolide B in the heterologous host Bacillus subtilis.

Kumpfmüller J, Methling K, Fang L, Pfeifer BA, Lalk M, Schweder T.

Appl Microbiol Biotechnol. 2016 Feb;100(3):1209-1220. doi: 10.1007/s00253-015-6990-6. Epub 2015 Oct 2.

28.

Contemporary approaches for nonviral gene therapy.

Jones CH, Hill A, Chen M, Pfeifer BA.

Discov Med. 2015 Jun;19(107):447-54. Review.

29.

Total Biosynthesis and Diverse Applications of the Nonribosomal Peptide-Polyketide Siderophore Yersiniabactin.

Ahmadi MK, Fawaz S, Jones CH, Zhang G, Pfeifer BA.

Appl Environ Microbiol. 2015 Aug 15;81(16):5290-8. doi: 10.1128/AEM.01373-15. Epub 2015 May 29.

30.

Influence of molecular weight upon mannosylated bio-synthetic hybrids for targeted antigen presenting cell gene delivery.

Jones CH, Gollakota A, Chen M, Chung TC, Ravikrishnan A, Zhang G, Pfeifer BA.

Biomaterials. 2015 Jul;58:103-11. doi: 10.1016/j.biomaterials.2015.04.033. Epub 2015 May 11.

31.

Improved Escherichia coli Bactofection and Cytotoxicity by Heterologous Expression of Bacteriophage ΦX174 Lysis Gene E.

Chung TC, Jones CH, Gollakota A, Kamal Ahmadi M, Rane S, Zhang G, Pfeifer BA.

Mol Pharm. 2015 May 4;12(5):1691-700. doi: 10.1021/acs.molpharmaceut.5b00172. Epub 2015 Apr 16.

PMID:
25849744
32.

Structure-Function Assessment of Mannosylated Poly(β-amino esters) upon Targeted Antigen Presenting Cell Gene Delivery.

Jones CH, Chen M, Gollakota A, Ravikrishnan A, Zhang G, Lin S, Tan M, Cheng C, Lin H, Pfeifer BA.

Biomacromolecules. 2015 May 11;16(5):1534-41. doi: 10.1021/acs.biomac.5b00062. Epub 2015 Apr 16.

PMID:
25848953
33.

PEGylated cationic polylactides for hybrid biosynthetic gene delivery.

Jones CH, Chen CK, Chen M, Ravikrishnan A, Zhang H, Gollakota A, Chung T, Cheng C, Pfeifer BA.

Mol Pharm. 2015 Mar 2;12(3):846-56. doi: 10.1021/mp500683c. Epub 2015 Feb 5.

PMID:
25625426
34.

Current and emerging options for taxol production.

Li Y, Zhang G, Pfeifer BA.

Adv Biochem Eng Biotechnol. 2015;148:405-25. doi: 10.1007/10_2014_292. Review.

PMID:
25528175
35.

Mannosylated poly(beta-amino esters) for targeted antigen presenting cell immune modulation.

Jones CH, Chen M, Ravikrishnan A, Reddinger R, Zhang G, Hakansson AP, Pfeifer BA.

Biomaterials. 2015 Jan;37:333-44. doi: 10.1016/j.biomaterials.2014.10.037. Epub 2014 Oct 22.

36.

Hybrid biosynthetic gene therapy vector development and dual engineering capacity.

Jones CH, Ravikrishnan A, Chen M, Reddinger R, Kamal Ahmadi M, Rane S, Hakansson AP, Pfeifer BA.

Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12360-5. doi: 10.1073/pnas.1411355111. Epub 2014 Aug 11.

37.

Porphyrin-phospholipid liposomes permeabilized by near-infrared light.

Carter KA, Shao S, Hoopes MI, Luo D, Ahsan B, Grigoryants VM, Song W, Huang H, Zhang G, Pandey RK, Geng J, Pfeifer BA, Scholes CP, Ortega J, Karttunen M, Lovell JF.

Nat Commun. 2014 Apr 3;5:3546. doi: 10.1038/ncomms4546.

38.

Synthesis of pH-responsive chitosan nanocapsules for the controlled delivery of doxorubicin.

Chen CK, Wang Q, Jones CH, Yu Y, Zhang H, Law WC, Lai CK, Zeng Q, Prasad PN, Pfeifer BA, Cheng C.

Langmuir. 2014 Apr 15;30(14):4111-9. doi: 10.1021/la4040485. Epub 2014 Apr 4.

PMID:
24665861
39.

Heterologous production of plant-derived isoprenoid products in microbes and the application of metabolic engineering and synthetic biology.

Li Y, Pfeifer BA.

Curr Opin Plant Biol. 2014 Jun;19:8-13. doi: 10.1016/j.pbi.2014.02.005. Epub 2014 Mar 12. Review.

PMID:
24631884
40.

Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Jones CH, Hakansson AP, Pfeifer BA.

J Mater Chem B. 2014;46:8053-8068. doi: 10.1039/C4TB01058B. Epub 2014 Sep 12.

41.

Polymyxin B treatment improves bactofection efficacy and reduces cytotoxicity.

Jones CH, Rane S, Patt E, Ravikrishnan A, Chen CK, Cheng C, Pfeifer BA.

Mol Pharm. 2013 Nov 4;10(11):4301-8. doi: 10.1021/mp4003927. Epub 2013 Oct 18.

42.

Overcoming nonviral gene delivery barriers: perspective and future.

Jones CH, Chen CK, Ravikrishnan A, Rane S, Pfeifer BA.

Mol Pharm. 2013 Nov 4;10(11):4082-98. doi: 10.1021/mp400467x. Epub 2013 Oct 16.

43.

Deoxysugar pathway interchange for erythromycin analogues heterologously produced through Escherichia coli.

Jiang M, Zhang H, Park SH, Li Y, Pfeifer BA.

Metab Eng. 2013 Nov;20:92-100. doi: 10.1016/j.ymben.2013.09.005. Epub 2013 Sep 20.

PMID:
24060454
44.

Poly(ethylene glycol)-block-cationic polylactide nanocomplexes of differing charge density for gene delivery.

Chen CK, Jones CH, Mistriotis P, Yu Y, Ma X, Ravikrishnan A, Jiang M, Andreadis ST, Pfeifer BA, Cheng C.

Biomaterials. 2013 Dec;34(37):9688-99. doi: 10.1016/j.biomaterials.2013.08.063. Epub 2013 Sep 10.

PMID:
24034497
45.

Improved heterologous erythromycin A production through expression plasmid re-design.

Jiang M, Fang L, Pfeifer BA.

Biotechnol Prog. 2013 Jul-Aug;29(4):862-9. doi: 10.1002/btpr.1759. Epub 2013 Jun 27.

PMID:
23804312
46.

Metabolic and pathway engineering to influence native and altered erythromycin production through E. coli.

Jiang M, Pfeifer BA.

Metab Eng. 2013 Sep;19:42-9. doi: 10.1016/j.ymben.2013.05.005. Epub 2013 Jun 5.

PMID:
23747605
47.

Engineering E. coli for triglyceride accumulation through native and heterologous metabolic reactions.

Rucker J, Paul J, Pfeifer BA, Lee K.

Appl Microbiol Biotechnol. 2013 Mar;97(6):2753-9. doi: 10.1007/s00253-013-4714-3. Epub 2013 Feb 13.

PMID:
23404315
49.

Synthesis of cationic polylactides with tunable charge densities as nanocarriers for effective gene delivery.

Jones CH, Chen CK, Jiang M, Fang L, Cheng C, Pfeifer BA.

Mol Pharm. 2013 Mar 4;10(3):1138-45. doi: 10.1021/mp300666s. Epub 2013 Feb 12.

PMID:
23339525
50.

Downstream reactions and engineering in the microbially reconstituted pathway for Taxol.

Jiang M, Stephanopoulos G, Pfeifer BA.

Appl Microbiol Biotechnol. 2012 May;94(4):841-9. doi: 10.1007/s00253-012-4016-1. Epub 2012 Mar 30. Review.

PMID:
22460591

Supplemental Content

Loading ...
Support Center